Expert Review of Clinical Immunology最新文献_第4页

Changes in health-related quality of life in common variable immunodeficiency: an eight-year journey, including the COVID-19 pandemic. 常见变异性免疫缺陷症患者与健康相关的生活质量变化：八年历程，包括 COVID-19 大流行。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-12 DOI: 10.1080/1744666X.2024.2368195

Federica Pulvirenti, Annalisa Villa, Matteo D'Ambrosi, Gabriella Cusa, Patricia Quijada-Morales, Eduardo de la Fuente-Munoz, Maddalena Sciannamea, Giulia Garzi, Isabella Quinti

{"title":"Changes in health-related quality of life in common variable immunodeficiency: an eight-year journey, including the COVID-19 pandemic.","authors":"Federica Pulvirenti, Annalisa Villa, Matteo D'Ambrosi, Gabriella Cusa, Patricia Quijada-Morales, Eduardo de la Fuente-Munoz, Maddalena Sciannamea, Giulia Garzi, Isabella Quinti","doi":"10.1080/1744666X.2024.2368195","DOIUrl":"10.1080/1744666X.2024.2368195","url":null,"abstract":"Background: Personalized medicine requires the assessment of the impact of health care interventions on Health-Related Quality of Life.Research design and methods: We run an observational study of HRQoL in 140 CVID patients with biannual assessments over 8 years using a disease-specific tool, the CVID_QoL, and the GHQ questionnaires. Factors influencing changes in HRQoL scores were identified using multiple linear regression models with a stepwise procedure.Results: Infections frequency, female gender, and chronic enteropathy were associated with worse global CVID_QoL scores. The presence of permanent organ damage and older age contributed to the perception of being at risk of health deterioration, while chronic enteropathy was associated with fatigue. The presence of permanent organ damage was also associated with perceived difficulties in usual activities. The frequency of infections was the main risk factor for difficulties in long-term planning and perceptions of vulnerability. Before COVID-19, improved HRQoL scores were associated with reduced respiratory infections and changes in immunoglobulin replacement route and setting. The COVID-19 pandemic caused a sudden deterioration in all HRQoL dimensions, and a further deterioration in the emotional dimension was observed during the pandemic period. Patients who died during the study had worse CVID_QoL scores at all time points, confirming that HRQoL performance is strongly related to patient outcome.Conclusions: Periodic HRQoL assessments are needed to capture relevant issues that change over time in patients affected by long-term chronic conditions such CVID, possibly identifying areas of intervention.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1269-1280"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141589972","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunological alterations in the endothelial barrier: a new predictive and therapeutic paradigm for sepsis. 内皮屏障的免疫学改变：脓毒症的新预测和治疗范例。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-06-11 DOI: 10.1080/1744666X.2024.2366301

Jun Feng, Lina Liu, Junya Liu, Junshuai Wang

{"title":"Immunological alterations in the endothelial barrier: a new predictive and therapeutic paradigm for sepsis.","authors":"Jun Feng, Lina Liu, Junya Liu, Junshuai Wang","doi":"10.1080/1744666X.2024.2366301","DOIUrl":"10.1080/1744666X.2024.2366301","url":null,"abstract":"Introduction: Despite the fact incidence and mortality vary widely among regions, sepsis remains a major cause of morbidity and cost worldwide. The importance of the endothelial barrier in sepsis and infectious diseases is increasingly recognized; however, the underlying pathophysiology of the endothelial barrier in sepsis remains poorly understood.Areas covered: Here we review the advances in basic and clinical research for relevant papers in PubMed database. We attempt to provide an updated overview of immunological alterations in endothelial dysfunction, discussing the central role of endothelial barrier involved in sepsis to provide new predictive and therapeutic paradigm for sepsis.Expert opinion: Given its physiological and immunological functions in infectious diseases, the endothelial barrier has been dramatically altered in sepsis, suggesting that endothelial dysfunction may play a critical role in the pathogenesis of sepsis. Although many reliable biomarkers have been investigated to monitor endothelial activation and injury in an attempt to find diagnostic and therapeutic tools, there are no specific therapies to treat sepsis due to its complex pathophysiology. Since sepsis is initiated by both hyperinflammation and immunoparalysis occurring simultaneously, a 'one-treatment-fits-all' strategy for sepsis-induced immune injury and immunoparalysis is bound to fail, and an individualized 'precision medicine' approach is required.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1205-1217"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141287971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Harnessing the power of AI-based models to accelerate drug discovery against immune diseases. 利用人工智能模型的力量，加快针对免疫疾病的药物研发。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-01 DOI: 10.1080/1744666X.2024.2373915

Philippe Moingeon

引用次数: 0

Treatment intensification in Kawasaki disease - current perspectives. 川崎病的强化治疗--当前视角。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI: 10.1080/1744666X.2024.2378900

Prabal Barman, Rakesh Kumar Pilania, Gayathri Cv, Abarna Thangaraj, Munish Arora, Surjit Singh

{"title":"Treatment intensification in Kawasaki disease - current perspectives.","authors":"Prabal Barman, Rakesh Kumar Pilania, Gayathri Cv, Abarna Thangaraj, Munish Arora, Surjit Singh","doi":"10.1080/1744666X.2024.2378900","DOIUrl":"10.1080/1744666X.2024.2378900","url":null,"abstract":"Introduction: Intravenous immunoglobulin is the standard of care in Kawasaki disease. However, a subset of patients exhibits resistance to intravenous immunoglobulin treatment, even when Kawasaki disease is promptly diagnosed and managed. While intravenous immunoglobulin reduces the occurrence of coronary artery abnormalities from 15-25% to 3-5%, it does not entirely eliminate the risk. Besides, management guidelines for non-coronary complications of Kawasaki disease, for instance, myocarditis, remain speculative.Areas covered: Recent literature suggests that a subset of patients with Kawasaki disease may benefit from treatment intensification with drugs, such as corticosteroids, infliximab, anakinra, and/or ciclosporin. In this manuscript, we have reviewed recent advances in the management of Kawasaki disease, especially with regard to preemptive intensification of therapy in children at high risk of cardiac complications. A comprehensive search was made using Web of Science, Scopus, and PubMed databases to gather English articles published from 1967 to 2023 on the treatment of Kawasaki disease. We incorporated the following words in the search strategy: 'Kawasaki disease,' 'intravenous immunoglobulin/IVIg,' 'intravenous immunoglobulin/IVIg-resistant Kawasaki disease,' 'treatment intensification,' or 'primary intensification of treatment/therapy.'Expert opinion: The 'high-risk' group in Kawasaki disease needs to be identified with early intensification of primary therapy for better coronary and myocardial outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1179-1191"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141558437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye. 强脉冲光与 0.05% 环孢素 a 外用眼药水联合治疗与斯约格伦综合征有关的干眼症的效果。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-05-27 DOI: 10.1080/1744666X.2024.2358157

Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin

{"title":"The effect of intense pulsed light combined with topical 0.05% Cyclosporin A eyedrops in the treatment of Sjögren's syndrome related dry eye.","authors":"Yanan Huo, Xiaodan Huang, Lin Lin, Shuo Yang, Zhenwei Qin, Zhu Yirui, Yujie Mou, Xiuming Jin","doi":"10.1080/1744666X.2024.2358157","DOIUrl":"10.1080/1744666X.2024.2358157","url":null,"abstract":"Objectives: This study aimed to assess the effectiveness and safety of intense pulsed light (IPL) therapy plus topical 0.05% cyclosporine A (CsA) eye drops to treat Sjögren's Syndrome-related dry eyes (SS-DE).Research design and methods: In this prospective, randomized trial included, 60 individuals with SS-DE symptoms were randomized to receive topical eye drops containing either 0.1% sodium hyaluronate (Group S) or 0.05% CsA (Group C) plus IPL therapy. Before the first treatment (baseline), and at 12, 16, and 20 weeks after treatment commencement, we assessed the best corrected visual acuity (BCVA), the Ocular Surface Disease Index (OSDI) score, the Schirmer I test (SIT), noninvasive tear breakup time (NBUT), corneal fluorescein staining (CFS), meibomian gland (MG) dropout, lid margin abnormality, MG expressibility, and meibum quality.Results: Both groups showed significant improvements in the OSDI, NBUT, CFS, MG expressibility, and meibum quality (all p < 0.05). Group C showed a greater increase in OSDI, NBUT, MG expressibility, and meibum quality (all p < 0.05). Moreover, SIT and lid margin abnormalities significantly improved in Group C (both p < 0.05), but not in Group S.Conclusion: Treatment with 0.05% CsA eyedrops plus IPL therapy could significantly reduce the issues and physical discomfort of patients with SS-DE.Clinical trial: Registered on 20 July 2021, with the registration number ChiCTR2100049059.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1261-1267"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Salivary gland biopsy as a prognostic tool in Sjögren's syndrome. 唾液腺活检作为斯约格伦综合征的预后工具。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-10-01 Epub Date: 2024-06-24 DOI: 10.1080/1744666X.2024.2368189

Roberto Dal Pozzolo, Giacomo Cafaro, Carlo Perricone, Santina Calvacchi, Lorenza Bruno, Anna Colangelo, Francesco Tromby, Roberto Gerli, Elena Bartoloni

{"title":"Salivary gland biopsy as a prognostic tool in Sjögren's syndrome.","authors":"Roberto Dal Pozzolo, Giacomo Cafaro, Carlo Perricone, Santina Calvacchi, Lorenza Bruno, Anna Colangelo, Francesco Tromby, Roberto Gerli, Elena Bartoloni","doi":"10.1080/1744666X.2024.2368189","DOIUrl":"10.1080/1744666X.2024.2368189","url":null,"abstract":"Introduction: Primary Sjögren's syndrome (pSS) is an autoimmune disorder primarily affecting salivary and lacrimal glands, although about 40% of patients experience systemic complications. In this setting, the identification of patient phenotypes characterized by increased risk of extra-glandular involvement still represents an unmet need.Areas covered: The aim of this paper is to review the scientific evidence on the utility of salivary gland biopsies in pSS, emphasizing their role in defining prognosis. In latest years, research focused on disease-specific clinical, serological, or histological features able to categorize patient prognosis. Among histopathological features, focus score and ectopic germinal centers exhibit associations with glandular and extraglandular manifestations, including higher rates of lymphomagenesis.Expert opinion: Pathological characterization of salivary glands provides information that go beyond a mere diagnostic or classification utility, providing insights for a stratification of disease severity and for predicting systemic manifestations. Thus, a salivary gland biopsy should be offered to all patients and included in routine practice, even when not strictly required for diagnostic purposes. More advanced analysis techniques of the tissue, including immunohistochemistry and 'omics' should be further explored in longitudinal studies to boost the ability to further stratify and predict disease evolution.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1139-1147"},"PeriodicalIF":3.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330697","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IL-10: the master immunomodulatory cytokine in allergen immunotherapy. IL-10：过敏原免疫疗法中的主要免疫调节细胞因子。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-25 DOI: 10.1080/1744666X.2024.2406894

Shixian Liu, Jingyun Li, Yuan Zhang, Chengshuo Wang, Luo Zhang

{"title":"IL-10: the master immunomodulatory cytokine in allergen immunotherapy.","authors":"Shixian Liu, Jingyun Li, Yuan Zhang, Chengshuo Wang, Luo Zhang","doi":"10.1080/1744666X.2024.2406894","DOIUrl":"https://doi.org/10.1080/1744666X.2024.2406894","url":null,"abstract":"Introduction: Allergen immunotherapy (AIT) is the only disease-modifying treatment for patients with IgE-mediated allergic diseases. Successful AIT can induce long-term immune tolerance to the common allergen, which provides clinical benefits for years after discontinuation. The cytokine interleukin (IL)-10, as a key anti-inflammatory mediator with strong immunoregulatory functions, has drawn increasing attention over the past decades.Areas covered: After an extensive search of PubMed, EMBASE, and Web of Science databases, covering articles published from 1989 to 2024, our review aims to emphasize the key common information from previous reviews on the crucial involvement of IL-10 in allergen immunotherapy (AIT) induced immunological tolerance. In this review, we discuss the regulation of IL-10 expression and the molecular pathways associated with IL-10 function. We also further summarize mechanisms of immune tolerance induced by AIT, especially the indispensable role of IL-10 in AIT.Expert opinion: IL-10 plays an indispensable role in immune tolerance induced by AIT. Understanding the importance of the role of IL-10 in AIT would help us comprehend the mechanisms thoroughly and develop targeted therapeutics for allergic diseases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-12"},"PeriodicalIF":3.9,"publicationDate":"2024-09-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142344366","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interstitial lung disease in rheumatic diseases: an update of the 2018 review. 风湿性疾病中的肺间质疾病：2018年回顾的更新。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-24 DOI: 10.1080/1744666X.2024.2407536

Fabiola Atzeni, Alessandra Alciati, Francesco Gozza, Ignazio Francesco Masala, Cesare Siragusano, Nicolò Pipitone

{"title":"Interstitial lung disease in rheumatic diseases: an update of the 2018 review.","authors":"Fabiola Atzeni, Alessandra Alciati, Francesco Gozza, Ignazio Francesco Masala, Cesare Siragusano, Nicolò Pipitone","doi":"10.1080/1744666X.2024.2407536","DOIUrl":"10.1080/1744666X.2024.2407536","url":null,"abstract":"Introduction: Interstitial lung disease (ILD) is a potential severe complication of various rheumatic diseases, typically connective tissue diseases (CTD), associated with significant morbidity and mortality. ILD may occur during the course of the disease but may also be its first manifestation. Several cell types are involved in ILD's pathogenesis, and if not controlled, pulmonary inflammation may lead to pulmonary fibrosis.Areas covered: We searched PubMed, Medline, and the Cochrane Library for papers published between 1995 and February 2017 in the first version, and between 2017 and April 2023 using combinations of words. The most frequent systemic rheumatic diseases associated with ILD are systemic sclerosis (SSc), rheumatoid arthritis (RA), and idiopathic inflammatory myositis. Treatment and monitoring guidelines are still lacking, and current treatment strategies have been extrapolated from the literature on SSc and established treatments for non-pulmonary systemic rheumatic manifestations.Expert opinion: Given the complexity of diagnosis and the paucity of treatment trials, managing CTD patients with ILD is challenging. It requires the skills of multidisciplinary CTD-ILD clinics including at least rheumatologists and lung specialists.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-18"},"PeriodicalIF":3.9,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282654","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Translational characterization of immune pathways in inflammatory bowel disease: insights for targeted treatments. 炎症性肠病免疫途径的转化特征：靶向治疗的启示。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-23 DOI: 10.1080/1744666X.2024.2400300

Sabrina Nicolò, Ilaria Faggiani, Carmela Errico, Ferdinando D'Amico, Tommaso Lorenzo Parigi, Silvio Danese, Federica Ungaro

{"title":"Translational characterization of immune pathways in inflammatory bowel disease: insights for targeted treatments.","authors":"Sabrina Nicolò, Ilaria Faggiani, Carmela Errico, Ferdinando D'Amico, Tommaso Lorenzo Parigi, Silvio Danese, Federica Ungaro","doi":"10.1080/1744666X.2024.2400300","DOIUrl":"https://doi.org/10.1080/1744666X.2024.2400300","url":null,"abstract":"Introduction: The pathogenesis of inflammatory bowel disease (IBD) involves the dysregulation of multiple inflammatory pathways. The understanding of these mechanisms allows their selective targeting for therapeutic purposes. The discovery of Tumor Necrosis Factor-alpha's (TNF-α) role in mucosal inflammation ushered an exciting new era of drug development which now comprises agents targeting multiple pro-inflammatory signaling pathways, integrins, and leukocyte trafficking regulators.Area covered: This review provides an overview of the main molecular players of IBD, their translation into therapeutic targets and the successful development of the advanced agents modulating them. We combine basic science with clinical trials data to present a critical review of both the successful and failed drug development programs. A PubMed literature search was conducted to delve into the available literature and clinical trials.Expert opinion: The treatment landscape for IBD has rapidly expanded, particularly with the development of biologics targeting TNF-α, integrins, and S1P modulators, as well as newer agents such as IL-12/IL-23 inhibitors and JAK inhibitors, offering robust efficacy and safety profiles. However, challenges persist in understanding and effectively treating difficult-to-treat IBD, highlighting the need for continued research to uncover novel therapeutic targets and optimize patient outcomes.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-18"},"PeriodicalIF":3.9,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142307412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Late effects following hematopoietic cell transplantation for severe combined immunodeficiency: critical factors and therapeutic options. 造血细胞移植治疗严重合并免疫缺陷症后的晚期效应：关键因素和治疗方案。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-22 DOI: 10.1080/1744666X.2024.2402948

Hesham Eissa, Morton J Cowan, Jennifer Heimall

{"title":"Late effects following hematopoietic cell transplantation for severe combined immunodeficiency: critical factors and therapeutic options.","authors":"Hesham Eissa, Morton J Cowan, Jennifer Heimall","doi":"10.1080/1744666X.2024.2402948","DOIUrl":"https://doi.org/10.1080/1744666X.2024.2402948","url":null,"abstract":"Introduction: Severe combined immunodeficiency (SCID) is an inborn error of immunity that is fatal without hematopoietic cell transplantation (HCT) or gene therapy (GT). Survival outcomes have improved, largely due to implementation of SCID newborn screening. A better understanding of the long-term outcomes and late effects to address critical aspects of monitoring immune and general health life-long is needed.Areas covered: In a comprehensive review of PubMed indexed articles with publication dates 2008-2024 we describe the current knowledge of chronic and late effects (CLE) of HCT survivors for SCID as well as the role of GT and advances for specific SCID genotypes. We review factors affecting the development of CLE including disease related factors (genotype, trigger for diagnosis and presence of infection prior to HCT), transplant related factors (type of donor, conditioning regimen, immune reconstitution and graft versus host disease (GVHD) and describe causes and factors associated with higher risk for late mortality in this unique population. We further describe monitoring and potential therapeutic strategies for management of common CLE in this patient population.Expert opinion: Ongoing research efforts are needed to better describe CLE in survivors, to develop prospective clinical trials aimed at mitigating these CLE, and developing genotype-based approaches for management and follow-up of these patients.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-10"},"PeriodicalIF":3.9,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142282655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0